Viewing Study NCT05092958


Ignite Creation Date: 2025-12-25 @ 12:22 AM
Ignite Modification Date: 2025-12-25 @ 10:25 PM
Study NCT ID: NCT05092958
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-11-17
First Post: 2021-10-22
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study
Sponsor: National Cancer Institute (NCI)
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module